MarketResearchNest.com adds “Interstitial Cystitis (Painful Bladder Syndrome) – Pipeline Review, H2 2017” new report to its research database. The report spread across 90 pages with table and figures in it.
Interstitial Cystitis (Painful Bladder Syndrome) – Pipeline Review, H2 2017
Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Interstitial Cystitis (Painful Bladder Syndrome) – Pipeline Review, H2 2017, provides an overview of the Interstitial Cystitis (Painful Bladder Syndrome) (Genito Urinary System And Sex Hormones) pipeline landscape.
Interstitial cystitis also called painful bladder syndrome is a chronic condition in which person experience bladder pressure, bladder pain and sometimes pelvic pain, ranging from mild discomfort to severe pain. Symptoms include decreased bladder capacity, painful sexual intercourse, chronic pelvic pain and a persistent, urgent need to urinate. Risk factors include age, gender and chronic pain disorder, such as irritable bowel syndrome or fibromyalgia. Treatment includes non-steroidal anti-inflammatory drug, antidepressants and antihistamines.
Browse full table of contents and data tables at
The Interstitial Cystitis (Painful Bladder Syndrome) (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 3, 6, 9 and 1 respectively.
Interstitial Cystitis (Painful Bladder Syndrome) (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Companies Involved in Therapeutics Development
Allergan Plc, Aquinox Pharmaceuticals Inc, Astellas Pharma Inc, BELLUS Health Inc, Idera Pharmaceuticals Inc, Kyorin Pharmaceutical Co Ltd, Kytogenics Pharmaceuticals Inc, Lipella Pharmaceuticals Inc, Merck & Co Inc, UCB SA, Urigen Pharmaceuticals Inc, Xigen SA.
Order a Purchase Report Copy at https://www.marketresearchnest.com/purchase.php?reportid=262560
Featured News & Press Releases
Aug 28, 2017: Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome
Oct 03, 2016: Aquinox Announces Appointment of Dr. Barbara Troupin as Chief Medical Officer
Sep 27, 2016: Idera Pharmaceuticals Presents New Third Generation Antisense (3GA) Data at the 12th Annual Meeting of the Oligonucleotide Therapeutics Society
Sep 06, 2016: Aquinox Pharmaceuticals Initiates Patient Dosing in LEADERSHIP 301 Phase 3 Clinical Trial of AQX-1125 in Interstitial Cystitis/Bladder Pain Syndrome
May 25, 2016: Aquinox Announces Executive Appointments
May 10, 2016: Aquinox Pharmaceuticals Announces First Quarter 2016 Financial Results
May 03, 2016: Allergan Presents New Data on LiRIS 400 mg at the American Urological Association Meeting in San Diego
Jan 11, 2016: Aquinox Announces Update on Development Program for AQX-1125 Following Meeting With FDA
Dec 22, 2015: Aquinox Pharmaceuticals Announces Appointment of Ms. Shelley McCloskey as Vice President, Human Resources & Administration
Sep 18, 2015: Aquinox Presents at 2015 International Society for the Study of BPS Conference
Aug 27, 2015: Lipella Pharmaceuticals Announces Enrollment of First Patient in Phase-2 Trial in Interstitial Cystitis
Aug 25, 2015: LEADERSHIP Results Accepted for Podium Presentation at the 2015 Annual Meeting of the International Society for the Study of BPS
Aug 06, 2015: Aquinox Pharmaceuticals Announces Positive Results From Secondary Endpoints From Phase 2 LEADERSHIP Trial in BPS/IC
Jul 28, 2015: Aquinox Pharmaceuticals to Provide Update on Secondary Endpoints From Phase 2 LEADERSHIP Trial in BPS/IC
Jun 25, 2015: Aquinox Pharmaceuticals Announces Results From LEADERSHIP Trial With AQX-1125 in Patients With Bladder Pain Syndrome/Interstitial Cystitis
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective RandD strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome) (Genito Urinary System And Sex Hormones).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Interstitial Cystitis (Painful Bladder Syndrome) (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Request a sample copy at
MarketResearchNest.com is the most comprehensive collection of market research products and service Interstitial Cystitis (Painful Bladder Syndrome) on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.
Mr. Jeet Jain